In the samples analyzed in our study, SCLC samples were identified as harboring TP53 alterations (more than 93% of the samples) with a frequency that is slightly higher than in the NSCLC specimens analyzed (87% of the samples) in the tumor tissue, but this tendency was not observed in the blood samples, TP53 being altered in 68% of SCLC and 81% of NSCLC samples (Figure 7). This evidence concerns the gene TP53 and non-small cell lung carcinoma.